At a glance
What do vitamin D receptors in the brain tell us?
Vitamin D receptors are part of the machinery that may allow the brain to respond to vitamin D. Their presence does not show how active that machinery is or whether supplements improve memory.
Can brain-cell or animal studies show that vitamin D prevents dementia?
They can test particular biological processes. They cannot establish prevention of dementia in people. A link between low vitamin D and later dementia may also have other explanations.
What did the human vitamin D trial find about thinking and memory?
The studies of thinking and memory within the large American trial did not establish an overall slowing of decline during the time they followed participants. This result concerns the people, treatment and tests studied; it does not answer every question about deficiency or brain disease.
Read the full article below ↓Brain studies of vitamin D range from receptor staining in human tissue to cognitive testing after years of supplementation. Each approach answers a different question. Reading them together is useful when the transitions between anatomy, cellular mechanisms and patient outcomes remain visible. A finding at one level does not automatically establish the next.
Begin with the question the model can answer
The brain overview brings several biological themes together. The evidence behind them can be organised by what was actually observed: the location of signalling components, a response in developing cells, injury under an experimental challenge, an association over time, or the effect of an assigned intervention. These are complementary questions, not interchangeable confirmations of cognitive benefit.
| Evidence setting | Useful question | Conclusion it cannot establish alone |
|---|---|---|
| Postmortem human brain tissue | Where are receptor and activating-enzyme signals detected? | That local hormone production is sufficient or supplementation improves cognition |
| Developing neuron cultures | How does a defined exposure alter cell growth or signalling? | That the same effect occurs during human development |
| Experimental neural injury | Does manipulating a pathway change injury-related outcomes in that model? | That an oral supplement treats a human brain disorder |
| Observational ageing cohorts | Does measured vitamin D status precede later cognitive differences? | That raising the blood concentration prevents dementia |
| Randomised supplementation studies | Does the assigned intervention change the specified outcome in eligible participants? | That every other population, exposure window or outcome has been tested |
Location provides a starting point, not a functional guarantee
Eyles and colleagues mapped receptor and activating-enzyme staining in a small set of human brains. The work supports anatomical plausibility and regional differences. A map of vitamin D receptors does not directly measure hormone availability, receptor activation or the amount of downstream signalling. The presence of the necessary machinery is a reason to investigate function, rather than proof of a clinical effect.
A functional experiment then asks whether changing an exposure changes a response. Pertile’s developing-neuron work illustrates that next step, including effects on neurites, the projections growing from neurons. Even here, results from primary neurons and engineered cell lines must remain distinct. An engineered model can isolate a process without reproducing the full environment of a developing human brain.
Mechanistic evidence depends on the intervention and model
Experiments that alter receptor abundance or stability can examine gene expression and downstream responses. Zheng’s work used cellular and animal injury models to investigate a receptor-related protective pathway. A receptor manipulation is different from changing nutritional intake, and an active-hormone exposure in culture is different from giving oral vitamin D3 to a person.
The same care applies to inflammatory signalling and oxidative stress. A particular inflammatory marker or oxidant-sensitive assay represents one part of those processes. A lower assay signal is not automatically a demonstration of complete neuroprotection. Ask which cells were studied, what challenge caused injury, when treatment occurred and which outcomes actually improved.
Human associations and intervention results address different claims
Longitudinal cohorts can examine whether low baseline vitamin D precedes cognitive decline or dementia. Littlejohns and colleagues provide one such example. Following people over time improves the temporal information, but underlying illness, activity and other factors can still affect both vitamin D status and later outcomes. Early disease may also change behaviour before a diagnosis becomes apparent.
Randomised studies test an assigned intervention more directly. The VITAL cognitive report did not establish an overall slowing of decline over its tested period. Its two ancillary assessment groups belong to one parent trial, so they should not be counted as two independent trials. A null overall result also leaves specific limits: eligibility, baseline status, duration and the sensitivity of the chosen cognitive tests define the question that was answered.
Connect the levels without skipping the missing steps
The concept of neuroendocrine integration helps connect circulating hormones with neural responses. Demonstrating that connection in a particular disease still requires appropriately timed evidence across the proposed pathway. Receptor staining plus a serum association does not establish that the receptor mechanism caused the observed human outcome.
Use the evidence hierarchy for the claim being assessed. Anatomical work can establish location, controlled models can test mechanisms, cohorts can identify risk markers and trials can assess assigned interventions. The strongest interpretation preserves what each design contributes and names what remains unmeasured. That approach allows biological plausibility and limited clinical benefit evidence to coexist without turning either into a stronger conclusion than the studies support.
Scientific sources
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain. Journal of Chemical Neuroanatomy. 2005;29:21 to 30. DOI: 10.1016/j.jchemneu.2004.08.006. PMID: 15589699. The complete published paper, seven figures and Table 1 were examined.
Pertile RAN, Brigden R, Raman V, Cui X, Du Z, Eyles D. Vitamin D: A potent regulator of dopaminergic neuron differentiation and function. Journal of Neurochemistry. 2023;166:779 to 789. DOI: 10.1111/jnc.15829. PMID: 37084159. The complete main paper and four figures were examined; the supplementary file was inaccessible and was not treated as independently verified.
Zheng Z, Chen M, Feng S, Zhao H, Qu T, Zhao X, Ruan Q, Li L, Guo J. VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease. Cell Death Discovery. 2024;10:150. DOI: 10.1038/s41420-024-01912-9. PMID: 38514643. The complete principal paper, seven figures, supplementary figures S1: S8 and supplementary tables S1: S3 were examined.
Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83:920 to 928. DOI:10.1212/WNL.0000000000000755. PMID:25098535. Complete principal paper, two figures and three tables examined; supplementary tables were inaccessible.
Kang JH, Vyas CM, Okereke OI, et al. Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial. Scientific Reports. 2021;11:23253. DOI:10.1038/s41598-021-02485-8. PMID:34853363. Complete principal paper, main figure, six tables and eight-page supplementary appendix examined. A validation plot cited in the appendix was not present in the retrieved file.
Related reading
A Risk Score for Predicting Multiple Sclerosis
Multiple sclerosis (MS) develops as a result of environmental influences on the genetically susceptible.
Original paper ↗Read more →An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ
Amyloid aggregation is associated with neurodegenerative disease and its modulation is a focus of drug development.
Original paper ↗Read more →Anti-inflammatory effects induced by pharmaceutical substances on inflammatory active brain astrocytes: promising treatment of neuroinflammation
Pharmaceutical treatment with probable anti-inflammatory substances that attack cells in various ways including receptors, ion channels, or transporter systems may slow down the progression of inflammatory conditions.
Original paper ↗Read more →Assessment of the Significance of LP-PLA2, DPYSL2, and 8-OHdG in the Oncological Diagnosis of Patients with Brain Tumors and Vitamin D Deficiency
This study aimed to assess the potential significance of DPYSL2, 8-OHdG, and LP-PLA2 in the oncological diagnosis of patients with brain tumors who have a vitamin D deficiency.
Original paper ↗Read more →Association of 25‐hydroxyvitamin D status with brain volume changes
The objective of this study was to evaluate the association between blood 25‐hydroxyvitamin D (25(OH)D) concentration and structural changes in the brain.
Original paper ↗Read more →Cross-sectional associations of plasma vitamin D with cerebral β-amyloid in older adults at risk of dementia
Participants were 178 dementia-free individuals aged 70 years or older with data on plasma 25(OH)D and cerebral Aβ load assessed by [18F]-florbetapir positron emission tomography.
Original paper ↗Read more →Determination of 25‐Hydroxyvitamin D3 in Rat Brain by Derivatization‐Assisted LC/ESI‐MS/MS
In normal rats (n = 6), the brain 25(OH)D3 concentrations ranged from 128 to 175 pg/g tissue, which were extremely low (approximately 1/100) compared to the serum concentrations.
Original paper ↗Read more →Effect of Sphingomyelin and Vitamin D3 Intake on the Rabbit Brain
In this study, the effect of a sphingomyelin + vitamin D3-enriched diet was investigated in rabbits.
Original paper ↗Read more →From armed-conflict to care: clinical outcomes, diagnostic challenges, and psychosocial burden in children evaluated for suspected cancer displaced from Gaza and treated at a regional center of excellence
Conflict-related displacement profoundly disrupts pediatric cancer care, yet clinical outcomes data for evacuated children treated at regional oncology centers remain scarce.
Original paper ↗Read more →In vivo discovery of blood-brain barrier opening small molecules with FishNAP
The blood: brain barrier (BBB) is crucial for neural homeostasis, tightly regulating molecular exchange between the circulation and brain.
Original paper ↗Read more →Interactions Between Blood Nutritional Biomarkers and Apolipoprotein E ε4 in the Progression of Mild Cognitive Impairment in Alzheimer’s Disease
Background/Objectives: Mild cognitive impairment (MCI), the prodromal stage of Alzheimer’s disease, may be influenced by nutritional status and genetic susceptibility.
Original paper ↗Read more →Life After Traumatic Brain Injury: Effects on the Lifestyle and Quality of Life of Community-Dwelling Patients
However, compared with the non-TBI group, the TBI group had a distinct lifestyle that involved increased reliance on analgesics (6.9% vs.
Original paper ↗Read more →Low serum 25‐hydroxyvitamin D3 levels and late delayed radiation‐induced brain injury in patients with nasopharyngeal carcinoma: A case-control study
Here, we aimed to determine the association of serum vitamin D levels with clinical parameters in late delayed RBI patients with nasopharyngeal carcinoma.
Original paper ↗Read more →Low Vitamin D Level Is Associated with Acute Deep Venous Thrombosis in Patients with Traumatic Brain Injury
Vitamin D and its association with venous thromboembolism (VTE) have been studied in common rehabilitation populations, such as spinal cord injury and ischemic stroke groups.
Original paper ↗Read more →Metabolomics Analysis of Hippocampus and Cortex in a Rat Model of Traumatic Brain Injury in the Subacute Phase
Traumatic brain injury (TBI) is a complex and serious disease as its multifaceted pathophysiological mechanisms remain vague.
Original paper ↗Read more →Mid-life serum Vitamin D concentrations were associated with incident dementia but not late-life neuropsychological performance in the Atherosclerosis Risk in Communities (ARIC) Study
We examined whether mid-life 25(OH) D concentrations were associated with later-life performance on neuropsychological testing, functional ability, depressive symptoms, and incident dementia.
Original paper ↗Read more →Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
To study which brain volume measures best differentiate early relapsing MS (RMS) and secondary progressive MS (SPMS) patients and correlate with disability and cognition.
Original paper ↗Read more →The Impact of Adult Vitamin D Deficiency on Behaviour and Brain Function in Male Sprague-Dawley Rats
The aim of this study was to investigate the effects of adult vitamin D (AVD) deficiency on behavioural tasks of relevance to neuropsychiatric disorders in male Sprague-Dawley rats.
Original paper ↗Read more →Vitamin D concentration and focal brain atrophy in older adults: a voxel‐based morphometric study
Our objective was to determine whether lower 25‐hydroxyvitamin D (25OHD) concentration was associated with focal brain volume reduction in older adults.
Original paper ↗Read more →Vitamin D Receptor Activation Influences NADPH Oxidase (NOX2) Activity and Protects against Neurological Deficits and Apoptosis in a Rat Model of Traumatic Brain Injury
In the present study, rats were randomly assigned to the sham, TBI, and calcitriol-treated groups.
Original paper ↗Read more →Vitamin D supplementation and serum neurofilament light chain in interferon‐beta‐1b‐treated MS patients
The aim of the present study was to address whether sNfL concentrations are affected by supplementation of vitamin D and correlate with disease activity in interferon‐beta‐1b (IFNb‐1b)‐treated Finnish MS.
Original paper ↗Read more →Original sources
Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain
Published in Journal of Chemical Neuroanatomy (2005).
Publication details
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain. Journal of Chemical Neuroanatomy. 2005;29:21 to 30. DOI: 10.1016/j.jchemneu.2004.08.006. PMID: 15589699. The complete published paper, seven figures and Table 1 were examined.
Vitamin D: A potent regulator of dopaminergic neuron differentiation and function
Published in Journal of Neurochemistry (2023).
Publication details
Pertile RAN, Brigden R, Raman V, Cui X, Du Z, Eyles D. Vitamin D: A potent regulator of dopaminergic neuron differentiation and function. Journal of Neurochemistry. 2023;166:779 to 789. DOI: 10.1111/jnc.15829. PMID: 37084159. The complete main paper and four figures were examined; the supplementary file was inaccessible and was not treated as independently verified.
VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease
Published in Cell Death Discovery (2024).
Publication details
Zheng Z, Chen M, Feng S, Zhao H, Qu T, Zhao X, Ruan Q, Li L, Guo J. VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease. Cell Death Discovery. 2024;10:150. DOI: 10.1038/s41420-024-01912-9. PMID: 38514643. The complete principal paper, seven figures, supplementary figures S1: S8 and supplementary tables S1: S3 were examined.
Vitamin D and the risk of dementia and Alzheimer disease
Published in Neurology (2014).
Publication details
Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83:920 to 928. DOI:10.1212/WNL.0000000000000755. PMID:25098535. Complete principal paper, two figures and three tables examined; supplementary tables were inaccessible.
Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial
Published in Scientific Reports (2021).
Publication details
Kang JH, Vyas CM, Okereke OI, et al. Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial. Scientific Reports. 2021;11:23253. DOI:10.1038/s41598-021-02485-8. PMID:34853363. Complete principal paper, main figure, six tables and eight-page supplementary appendix examined. A validation plot cited in the appendix was not present in the retrieved file.